Willingness to Pay for a Treatment for Pain in Multiple Sclerosis

Michael Iskedjian,Olivier Desjardins,Charles Piwko,Basil Bereza, Barbara Jaszewski,Thomas R. Einarson

PharmacoEconomics（2009）

引用 8|浏览11

暂无评分

摘要

Background: Multiple sclerosis (MS) is a chronic neurological disease that affects 240 per 100 000 Canadians. Of these patients, 10–80% (average 70%) experience pain. Sativex® is a cannabis-based drug recently approved for neuropathic pain.

查看译文

关键词

Multiple Sclerosis,Multiple Sclerosis Patient,Gabapentin,Insurance Premium,Decision Board

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要